Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort ...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today a long-term extension of its collaboration with a major global biopharmaceutical partner ...

The Lonza plant at Visp, deep in the Swiss Alps, is a hive of activity. Workers are racing to set up production lines to be able to start making a Covid-19 vaccine for US firm Moderna later this year.

Morgan Stanley analyst Thibault Boutherin has maintained their bullish stance on LONN stock, giving a Buy rating on October 17. Thibault ...

Lonza has boosted its ability to cater for customers ... which provides manufacturing services to the category from facilities in Visp, Switzerland. The group is paying €100 million ($107 ...

The acquisition of the large-scale mammalian manufacturing site complements Lonza’s ongoing investments in large-scale bioconjugation in Visp (CH) and drug product manufacturing in Stein (CH), ...

Roche is set to raise $1.2 billion from the sale of a US biologics manufacturing facility to Swiss contract development and manufacturing organisation (CDMO) Lonza, part of a drive to match ...

The main production facility for drug manufacturer Lonza in Visp recently adopted a similar policy. As of 2018, employees at this factory, whose workforce has grown significantly in recent years ...

(RTTNews) - Lonza Group (LZAGF.PK), a Swiss manufacturer focused on the pharmaceutical and nutrition businesses, on Thursday reported that its third-quarter performance was in line to deliver on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...